| Literature DB >> 27121107 |
Karen Grimmer1,2, Shingai Machingaidze3,4, Janine Dizon5,6, Tamara Kredo3, Quinette Louw7,4, Taryn Young7,5.
Abstract
BACKGROUND: Critically appraising the quality of clinical practice guidelines (CPGs) is an essential element of evidence implementation. Critical appraisal considers the quality of CPG construction and reporting processes, and the credibility of the body of evidence underpinning recommendations. To date, the focus on CPG critical appraisal has come from researchers and evaluators, using complex appraisal instruments. Rapid critical appraisal is a relatively new approach for CPGs, which targets busy end-users such as service managers and clinicians. This paper compares the findings of two critical appraisal instruments: a rapid instrument (iCAHE) and a complex instrument (AGREE II). They were applied independently to 16 purposively-sampled, heterogeneous South African CPGs, written for eleven primary health care conditions/health areas. Overall scores, and scores in the two instruments' common domains Scope and Purpose, Stakeholder involvement, Underlying evidence/Rigour of Development, Clarity), were compared using Pearson r correlations and intraclass correlation coefficients. CPGs with differences of 10 % or greater between scores were identified and reasons sought for such differences. The time taken to apply the instruments was recorded.Entities:
Keywords: AGREE II; CPG quality; Clinical practice guidelines (CPGs); Complex appraisal tool; Primary health care; Rapid appraisal tool, iCAHE checklist; Reporting standards; South Africa
Mesh:
Year: 2016 PMID: 27121107 PMCID: PMC4848797 DOI: 10.1186/s13104-016-2053-z
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
iCAHE questions mapped against AGREE II domains and their statements
| iCAHE | AGREE II | |
|---|---|---|
| AGREE II domain 1: scope and purpose | Q13 Are the purpose and target users of the guideline stated? | Q1. The overall objectives of the guideline are specifically described |
| Q2. The health questions covered by the guideline are specifically described | ||
| Q3. The population to whom the guideline is meant to apply is specifically described | ||
| AGREE II domain 2: stakeholder involvement | Q6. The target users are clearly defined | |
| Q11. Are the developers clearly stated? | Q4. The guideline development group includes individuals from all relevant professional groups | |
| Q12. Does the qualifications and expertise of the guideline developers link with the purpose of the guideline and its end users? | Q5. The views and preferences of the target population have been sought | |
| AGREE II domain 3: rigour of development | Q7. Does the guideline provide an outline of the strategy used to find underlying evidence? | Q7. Systematic methods were used to search for the evidence |
| Q8. Does the guideline use a hierarchy to rank the quality of the underlying evidence? | Q8. The criteria for selecting the evidence are clearly described | |
| Q9. Does the guideline appraise the quality of the evidence which underpins its recommendations? | Q9. The strengths and limitations of the body of evidence are clearly described | |
| Q10. Does the guideline link the hierarchy and quality of underlying evidence to each recommendation? | Q10. The methods for formulating the recommendations are clearly described | |
| Q11. The health benefits, side effects and risks have been considered in formulating the recommendations | ||
| Q12. There is an explicit link between the recommendations and the supporting evidence | ||
| Q13. The guideline has been eternally reviewed by experts prior to its publication | ||
| Q14. A procedure for updating the guideline is provided | ||
| iCAHE instrument domain: currency | Q4. Is there a date of completion available? | |
| Q5. Does the guideline provide an anticipated review date? | ||
| Q6. Does the guideline provide dates for when literature was included? | ||
| AGREE II domain 4: clarity of presentation | Q14. Is the guideline readable and easy to navigate? | Q15. The recommendations are specific and unambiguous |
| Q16. The different options for management of the condition or health issues are clearly presented | ||
| Q17. Key recommendations are easily identifiable | ||
| AGREE II domain 5: applicability | Q18. The guideline describes facilitators and barriers to its application | |
| Q19. The guideline provides advice and/or tools on how the recommendations can be put into practice | ||
| Q20. The potential resources implications of applying the recommendations have been considered | ||
| Q21. The guideline presents monitoring and/or auditing criteria | ||
| AGREE II domain 6: editorial independence | Q22. The views of the funding body have not influenced the content of the guideline | |
| Q23. Competing interests of guideline development group members have been recorded and addressed | ||
| iCAHE instrument domain: availability | Q1. Is the guideline readily available in full text? | |
| Q2. Does the guideline provide a complete reference list? | ||
| iCAHE instrument domain: summary | Q3. Does the guideline provide a summary of its recommendations? |
Adapted from Grimmer et al. [17]
South African CPGs included in this analysis (reproduced from Machingaidze et al. [22])
| Name | Short name | Publication year | Developer |
|---|---|---|---|
|
| |||
| Clinical guidelines for the management of HIV and AIDS in adults and adolescents | Adult HIV | 2010 | National Department of Health |
| Guidelines for the management of HIV in children | Child HIV | 2010 | National Department of Health |
| Clinical guidelines: PMTCT (prevention of mother-to-child transmission) | PMTCT | 2010 | National Department of Health |
| National tuberculosis management guidelines | Adult TB | 2014 | National Department of Health |
| Guidelines for the management of tuberculosis in children | Child TB | 2013 | National Department of Health |
| Malaria prevention guidelines | Malaria prevention | 2011 | National Department of Health |
| Malaria treatment guidelines | Malaria treatment | 2010 | National Department of Health |
|
| |||
| Standard treatment guidelines and essential medicines list for South Africa | EDL | 2008 | National Department of Health |
| Integrated management of childhood illnesses | IMCI | 2002 | National Department of Health |
| Guidelines for maternity care in South Africa | Maternal | 2007 | National Department of Health |
| Primary care 101 | PC101 | 2013 | UCT Lung Institute/National Department of Health |
|
| |||
| Guideline for the management of acute asthma in adults: 2013 update | Adult asthma | 2013 | South African Thoracic Society |
| Guideline for the management of acute asthma in children: 2013 update | Child asthma | 2013 | South African Thoracic Society |
| Guideline for the management of chronic obstructive pulmonary disease—2011 update | COPD | 2011 | South African Thoracic Society |
| South African hypertension guideline 2011 | Hypertension | 2011 | Southern African Hypertension Society |
| The 2012 SEMDSA guideline for the management of type 2 diabetes (Revised) | Type II diabetes | 2012 | Society for endocrinology, metabolism and diabetes of South Africa |
CPG scores for iCAHE questions mapped against AGREE II domains
| Domains | iCAHE questions | Disease specific guidelines | Combination guidelines | Guidelines by professional societies | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adult HIV | Child HIV | PMTCT | Adult TB | Child TB | Malaria prevention | Malaria treatment | EDL | IMCI | Maternal | PC101 | Adult asthma | Child asthma | COPD | Hypertension | Type II diabetes | ||
| AGREE II domain 1: scope and purpose | Q13 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| AGREE II domain 2: stakeholder involvement | Q11 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Q12 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | |
| AGREE II domain 3: rigour of development | Q7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Q8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | |
| Q9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Q10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| New iCAHE domain: currency | Q4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Q5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Q6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| AGREE II domain 4: clarity of presentation | Q14 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| New iCAHE domain: summary | Q3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| New iCAHE domain: availability | Q1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Q2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |
| Guideline % scorea | 36 | 36 | 43 | 29 | 36 | 57 | 57 | 36 | 36 | 43 | 43 | 57 | 71 | 50 | 57 | 57 | |
1 Yes (criterion was addressed), 0 No (criterion not addressed)
aDomain percentage scores are calculated as the total number of yes questions divided by the total number of possible questions and converted into a percentage
Fig. 1Analysis 1 findings: comparison of % of total scores per CPG, including all questions (iCAHE instrument) and statements (AGREE II)
Fig. 2Analysis 2 findings: comparison of % of total scores per CPG for the common domains only
Pearson r correlation coefficients, ICC(2,1) values for agreement and CPGs with disagreements >10 %, listed by order of size of disagreement for analyses 1 and 2
| Pearson r correlation coefficient | Agreement expressed as ICC(2,1) values | CPGs with disagreements > 10 % between instruments | Size of disagreement (-ve values in favour of AGREE II) (%) | |
|---|---|---|---|---|
| Analysis 1: using all statements in both instruments |
|
|
| |
| Child asthma | 34.8 | |||
| Adult asthma | 23.3 | |||
| Malaria treatment | 22.7 | |||
| Malaria prevention | 18.9 | |||
| COPD | 17.4 | |||
| Hypertension | 17.1 | |||
| Analysis 2: using only the statements in the common domains between the instruments |
|
|
| |
| Child asthma | 17.1 | |||
| Adult asthma | 10.9 | |||
| Adult HIV | −14.5 | |||
| Child HIV | −15.3 | |||
| PMTCT | −15.3 | |||
| PC101 | −24.7 | |||
| Adult TB | −29.0 | |||